Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Heart failure affects an estimated 64.3 million people worldwide
The approval introduces a needle-free alternative to injectable GLP-1 therapies
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Subscribe To Our Newsletter & Stay Updated